Mass Tort brief
State AGs and Bellwether Juries Accelerate Multidistrict Liability Pressure
As Meta faces a $1T state trial and Medtronic hits an $88M hernia mesh verdict, federal MDL dockets tighten trial prep across medical devices and consumer products.
Mass Tort
Mass Tort
An $88 million bellwether verdict against Medtronic's hernia mesh unit sets a steep financial benchmark — forcing the manufacturer toward high-value settlements across 10,000 pending claims.
BackgroundMultidistrict litigation centralizes thousands of product liability lawsuits alleging medical device design defects and failure to warn doctors. Bellwether trials serve as test cases to establish settlement valuation benchmarks across consolidated dockets.
- The $88 million award in Patterson v. Covidien represents the largest compensatory verdict in U.S. hernia mesh history, raising settlement expectations.
- Presiding Judge Patti Saris oversaw the trial focused on severe chronic pain and surgical revision injuries caused by Symbotex mesh design defects.
- Medtronic announced plans to appeal while facing roughly 2,400 federal lawsuits and 7,450 state court claims across consolidated jurisdictions.
Mass Tort
A second bellwether trial testing catheter migration injuries will evaluate device design defects — setting settlement pressure across nearly 4,000 pending PowerPort lawsuits.
BackgroundVascular access port catheters are implanted under the skin to deliver chemotherapy and medications directly into bloodstream veins. Centralized claims allege Becton Dickinson subsidiary C.R. Bard used vulnerable barium sulfate plastic formulations prone to fracturing.
- The lawsuit Divelbliss v. C.R. Bard tests catheter port fracture and internal organ migration allegations before Judge David Campbell in Phoenix.
- Judicial panel data shows centralized federal claims against C.R. Bard have grown to 3,734 pending lawsuits awaiting trial outcome metrics.
- Outcome data from early bellwether trials will establish binding valuation parameters for nationwide settlement negotiations across the centralized docket.
Mass Tort
Stalled settlement negotiations forced federal courts to unfreeze discovery — pushing cosmetic manufacturers toward public trials across nearly 12,000 pending hair relaxer cancer claims.
BackgroundHair straightening products containing phthalates and endocrine-disrupting chemicals have been linked to hormone-sensitive cancers in women. Plaintiffs allege cosmetic manufacturers marketed chemical straighteners despite knowing long-term uterine cancer and fibroid risks.
- Centralized claims in MDL No. 3060 reached 11,779 pending federal cases in Illinois court, making it one of the largest active dockets.
- Judge Mary Rowland lifted discovery stays after settlement discussions failed to produce significant progress, forcing defendants back into trial preparation.
- Expert discovery and bellwether trial selections are actively proceeding against major cosmetic manufacturers to evaluate liability for chemical straightener harms.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
